文献速递自身免疫性与大疱性皮肤病

多激酶抑制剂米哚妥林减轻寻常型天疱疮的细胞间黏附丧失与皮肤水疱形成

The Multikinase Inhibitor Midostaurin Mitigates Loss of Intercellular Adhesion and Skin Blistering in Pemphigus Vulgaris.
PubMed 文献 · J Invest Dermatol · 2025-05-29

本研究探索多激酶抑制剂米哚妥林作为天疱疮治疗选择的潜力。体外实验显示米哚妥林可挽救寻常型与落叶型天疱疮IgG诱导的角质形成细胞黏附丧失和角蛋白回缩。离体人皮肤中米哚妥林预防寻常型天疱疮IgG诱导的水疱形成,超微结构分析显示其恢复桥粒完整性。

要点

  • 米哚妥林可挽救天疱疮IgG诱导的角质形成细胞黏附丧失。
  • 米哚妥林预防离体人皮肤中寻常型天疱疮IgG诱导的水疱形成。
  • 米哚妥林恢复桥粒超微结构完整性。

核心结论

  • 米哚妥林可对抗天疱疮自身抗体的致病效应,提示其作为天疱疮治疗药物的潜力。

研究设计与样本

  • 本研究为体外与离体实验研究,使用培养的角质形成细胞和离体人皮肤,检测米哚妥林对天疱疮IgG诱导的黏附丧失和水疱形成的影响。

主要发现

  • 米哚妥林有效挽救寻常型天疱疮和落叶型天疱疮IgG诱导的培养角质形成细胞黏附丧失和角蛋白回缩。
  • 米哚妥林预防寻常型天疱疮IgG介导的桥粒芯蛋白3在细胞膜内的重新定位以及单分子水平上桥粒芯蛋白3黏附的丧失。
  • 在离体人皮肤中,米哚妥林处理成功预防寻常型天疱疮IgG诱导的水疱形成。
  • 超微结构分析显示米哚妥林恢复桥粒的完整性。

临床怎么用

  • 米哚妥林可能作为天疱疮的潜在治疗药物,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pemphigus is a group of autoimmune blistering diseases characterized by the presence of autoantibodies against desmogleins, which are critical components of desmosomes. These autoantibodies disrupt the adhesive function of desmosomes, leading to loss of cell-cell adhesion in the epidermis, which manifests clinically as blistering and erosions of the skin and mucous membranes. In this study, we explored the potential use of midostaurin, a multikinase inhibitor commonly employed in the treatment of FLT3-altered cancers, as a therapeutic option for pemphigus. The results demonstrated that midostaurin effectively rescued loss of adhesion and keratin retraction induced by both pemphigus vulgaris and pemphigus foliaceus IgG in cultured keratinocytes. In addition, midostaurin prevented pemphigus vulgaris IgG-mediated relocalization of desmoglein 3 within the cell membrane as well as loss of desmoglein 3 adhesion on single-molecule level as revealed by atomic force microscopy. In ex vivo human skin, midostaurin treatment successfully prevented pemphigus vulgaris IgG-induced blister formation. Ultrastructural analyses revealed that midostaurin restored the integrity of desmosomes. These findings indicate that midostaurin can counteract the pathogenic effects of pemphigus autoantibodies, suggesting its potential as a therapeutic agent for pemphigus.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Hiermaier M, Egu DT, Sigmund AM, et al. The Multikinase Inhibitor Midostaurin Mitigates Loss of Intercellular Adhesion and Skin Blistering in Pemphigus Vulgaris. J Invest Dermatol. 2025. PMID: 40449656. doi:10.1016/j.jid.2025.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。